Search
Regenxbio Inc
RGNXAdd to Watchlist
13.280USD
+0.190+1.45%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
686.54MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.45%
5 Days
+29.69%
1 Month
+103.68%
6 Months
-2.14%
Year to Date
-7.78%
1 Year
+54.06%
Key Figures
13.640Open
14.250High
3.30MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
6.48%Turnover Ratio
13.090Prev. Close
13.165Low
29.30MTurnover
LossP/E Static
6.58P/B
0.00%Div Yield TTM
-69.65%ROA
16.19052wk High
2.10Volume Ratio
-227.10MNet Profit
50.89MShares
-5.5953EPS TTM
1.05Beta
-196.43%ROE
5.45552wk Low
8.29%Amplitude
-73.22%Gross Margin
686.54MMarket Cap
21.00Reward/Risk
4.56%Risk Rate
TradingKey Stock Score of Regenxbio Inc
Currency: USD Updated: 2026-07-02Key Insights
Regenxbio Inc's fundamentals are relatively weak, and its growth potential is significant.Its valuation is considered fairly valued, ranking 97 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.25.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Regenxbio Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Regenxbio Inc Highlights
StrengthsRisks
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 88.87% year-on-year.
Fairly Valued
The company’s latest PE is -2.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 45.28M shares, decreasing 7.13% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 62.96K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.53.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
26.250
Target Price
+121.89%
Upside Space
Regenxbio Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Regenxbio Inc Info
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Ticker SymbolRGNX
CompanyRegenxbio Inc
CEOSimpson (Curran M)
Websitehttps://regenxbio.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52821.700
-20.800 (-0.04%)
29616.800
+305.400 (+1.04%)
7498.300
+26.800 (+0.36%)
14954.000
+151.000 (+1.02%)
69503.000
+1355.000 (+1.99%)
6370.700
+17.900 (+0.28%)
68.563
+0.219 (+0.32%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4180.120
+58.210 (+1.41%)
FAQs
What is the current price of Regenxbio Inc (RGNX)?
The current price of Regenxbio Inc (RGNX) is 13.28.
What is the symbol of Regenxbio Inc?
The ticker symbol of Regenxbio Inc is RGNX.
What is the 52-week high of Regenxbio Inc?
The 52-week high of Regenxbio Inc is 16.19.
What is the 52-week low of Regenxbio Inc?
The 52-week low of Regenxbio Inc is 5.46.
What is the market capitalization of Regenxbio Inc?
The market capitalization of Regenxbio Inc is 675.85M.
Is Regenxbio Inc (RGNX) currently rated as Buy, Hold, or Sell?
According to analysts, Regenxbio Inc (RGNX) has an overall rating of Buy, with a price target of 26.25.
What is the Earnings Per Share (EPS TTM) of Regenxbio Inc (RGNX)?
The Earnings Per Share (EPS TTM) of Regenxbio Inc (RGNX) is -3.76.